English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In recent years, regadenoson has increasingly penetrated the clinical market as a novel pharmacologic stress agent for myocardial perfusion imaging (MPI).1 Regadenoson has favourable features such as a rapid onset of vasodilation with sustained action, enabling injection as a slow bolus,1 and a preferable side-effect profile when compared with adenosine due to adenosine A2A receptor subtype selectivity.2 Another advantage is that it can be used in obstructive pulmonary disease, when the traditional agents dypiridamole and adenosine may be unsafe.3Many studies investigating regadenoson in different risk groups, using various imaging protocols and nuclear tracers, demonstrated safety and efficacy comparable with adenosine for the detection of reversible myocardial perfusion defects.2 More recently, regadenoson, despite its predominantly renal clearance, was also shown to be well tolerated in patients with chronic renal failure (CRF).4 Because CRF patients are generally at a higher risk for cardiovascular events, the value of MPI in this group has been actively investigated in recent years. Using exercise …

Further evidence for the robustness of regadenoson stress myocardial perfusion SPECT: its predictive value for cardiac events in chronic renal failure